Health Care • Biotechnology: Laboratory Analytical Instruments
$62.00 ▲ +0.00
(0.00%)
MKT CAP: $9.45B • VOL: 1.50M
52W L $32 52W H $67
BRKR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.44B | $3.37B | $2.96B |
| YoY Revenue Growth % | +2.1% | +13.6% | — |
| Gross Profit | $1.58B | $1.65B | $1.30B |
| Gross Margin % | 45.9% | 49.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $68.2M | $253.1M | $436.9M |
| Operating Margin % | 2.0% | 7.5% | 14.7% |
| Net Income (GAAP) | -$8.3M | $113.8M | $428.5M |
| EBITDA (Normalized) | $140.8M | $345.3M | $543.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $134.1M | $251.3M | $350.1M |
| Capital Expenditures (CapEx) | $90.8M | $115.3M | $133.4M |
| Free Cash Flow (FCF) | $43.3M | $136.0M | $216.7M |
| FCF Margin % | 1.3% | 4.0% | 7.3% |
| Return on Invested Capital (ROIC %) | 1.3% | 5.5% | 11.0% |
| Cash & Short-Term Equivalents | $298.8M | $183.4M | $571.5M |
| Total Debt (Short + Long Term) | $1.85B | $2.06B | $1.22B |
| Total Stockholders' Equity | $2.46B | $1.78B | $2.49B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BRKR.